Bacterial lysate immunotherapy for infectious disease prevention
OM Pharma develops immunotherapies based on bacterial lysates, targeting respiratory and urinary tract infections across 100+ countries. The tech stack is heavily operational—Tracelink, Veeva, SAGE X3, SCADA/PLC—reflecting a pharma manufacturer managing manufacturing compliance, ERP stability, and serialization at scale. Active hiring across sales, marketing, and engineering, plus a leadership-tier recruitment in Medical Affairs and analytics, signals expansion in clinical strategy and data infrastructure alongside core manufacturing challenges.
Notable leadership hires: Medical Affairs Lead, Analytics Lead, Head of Medical Affairs, Commercial Head
OM Pharma is a Swiss pharmaceutical manufacturer founded in 1937, headquartered in Meyrin with affiliates in Peru. The company specializes in bacterial lysate therapies for immune system modulation, currently focused on prevention of respiratory and urinary tract infections. Products are distributed through a partner network across more than 100 countries. Operations span manufacturing, regulatory, medical affairs, and commercial functions, supported by a 201–500 person workforce across Switzerland, Peru, Costa Rica, and El Salvador.
OM Pharma develops bacterial lysate immunotherapies for prevention of respiratory and urinary tract infections, with expansion into additional indications and formulations based on immune system research.
Headquartered in Meyrin, Geneva, Switzerland, with affiliates in Peru. Products are available in more than 100 countries via partner distribution networks.
OM Pharma operates on SAGE X3 for ERP, Veeva Vault and Veeva for regulatory/quality management, Tracelink for supply chain compliance, and SCADA/PLC systems for manufacturing control.
Other companies in the same industry, closest in size